2seventy bio, Inc. (NASDAQ:TSVT) CFO Sells $12,830.40 in Stock

2seventy bio, Inc. (NASDAQ:TSVT) CFO Victoria Eatwell sold 2,592 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $4.95, for a total transaction of $12,830.40. Following the completion of the transaction, the chief financial officer now directly owns 444,387 shares of the company’s stock, valued at approximately $2,199,715.65. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

2seventy bio Price Performance

NASDAQ:TSVT opened at $4.96 on Thursday. 2seventy bio, Inc. has a 12-month low of $2.29 and a 12-month high of $5.99. The stock’s 50 day moving average price is $2.85 and its two-hundred day moving average price is $3.69. The firm has a market capitalization of $255.88 million, a price-to-earnings ratio of -2.67 and a beta of 1.73.

Institutional Investors Weigh In On 2seventy bio

Large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP acquired a new position in shares of 2seventy bio in the third quarter valued at $64,000. Intech Investment Management LLC bought a new stake in shares of 2seventy bio during the 3rd quarter worth about $69,000. FMR LLC grew its stake in 2seventy bio by 22.0% in the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares during the last quarter. BBR Partners LLC raised its holdings in 2seventy bio by 620.0% in the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after acquiring an additional 155,000 shares during the period. Finally, PDT Partners LLC acquired a new stake in 2seventy bio during the third quarter worth approximately $244,000. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Leerink Partnrs cut 2seventy bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 11th. Morgan Stanley decreased their price target on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Friday, March 14th. Leerink Partners reissued a “market perform” rating and issued a $5.00 price objective (down previously from $9.00) on shares of 2seventy bio in a research report on Tuesday, March 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.67.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.